EN
The objective of clinical observations was to evaluate Lydium-KLP (NIKA) usefulness in treatment of some tumors in pets. The active ingredient of Lydium-KLP is the lysozyme dimer that affects various mechanisms of cellular and humoral defense. The research concerned a group of 118 dogs and 18 cats with neoplastic changes that differed in progress and malignancy level. The animals were divided into three groups: a control group and two experimental groups. The control group (41 animals) was treated with the conventional method composed of surgical procedure (removing tumors and other changed tissue) and applications of protective and palliative drugs. The first experimental group consisting of 37 dogs and cats was treated with surgical procedure and then with injections of Lydium-KLP (at least 8 times) in doses of 20-40 pg/kg b.w. i.m. or s.c. (combined method). The second experimental group was made up of 40 dogs and cats. In this case the conservative method (only Lydium-KLP injections) was implemented. The effectiveness was checked for the period of 6-24 months after the therapy had been carried out. The combined method appeared to be the most effective (67.6% of recovery) followed by the conventional (61.0%) and conservative one (45%). Lysozyme dimer injections led to quicker recoveries of surgically treated animals. As a consequence of the combined therapy there were fewer recidivations, metastasises, and postoperative complications, as compared with the conventional treatment. The conservative therapy resulted in progress termination or even regression of tumors like adenocarcinoma, adenofibroma, seminoma and papilloma. The results of these obervations indicate the validity of continuing research on the application of lysozyme dimer (Lydium-KLP) in treatment of animals affected by neoplasms.